34 results about "Microdosing" patented technology

A volume sensor-free microdosing device comprises a pressure chamber which is at least partly delimited by a displacer, an actuating device for actuating the displacer, the volume of the pressure chamber being adapted to the changed by actuating the displacer, a media reservoir which is in fluid communication with the pressure chamber, an outlet opening which is in fluid communication with the pressure chamber, and a control mechanism. The control mechanism drives the microdosing device in such a way that a small change of volume of the pressure chamber volume is effected per unit time by a movement of the displacer from a first position to a predetermined second position, the second position of the displacer defining a larger volume of the pressure chamber than the first position, so as to suck a fluid volume into the pressure chamber, and that, in a second phase, a large volume change of the pressure chamber volume is effected per unit time by a movement of the displacer from the second position to the first position, so as to eject a defined fluid volume from the outlet opening in this way.

A microdosing apparatus comprises a fluid conduit having a flexible tube with a first end for connecting to a fluid reservoir and a second end where an outlet opening is located. An actuating device with a displacer with adjustable hub is provided, by which the volume of a portion of the flexible hub can be changed to thereby dispense liquid as free flying droplets or as free flying jet at the outlet opening by moving the displacer between a first end position and a second end position, whereby the tube is partly compressed in the first or the second end position. In other words, a microdosing apparatus comprises fluid conduit having a portion along which a cross section of the fluid conduit is variable by an actuating device to effect a change of the volume of the fluid conduit. A ratio of a fluidic impedance between the position of the actuating device and the outlet opening to a fluidic impedance between a first end of the fluid conduit and the position of the actuating device is variable by changing the position of the actuating device, so that a dosing volume dispensed at the outlet opening is variable thereby by at least 10%.

The invention relates to an insulin pump (1) with an infusion set adapter (21) having a diaphragm (7) exposed to the liquid path (2). Arranged in the housing (20) of the insulin pump (1) is a measurement arrangement comprising emitter (4) and sensor (5), by means of which a bowing of the diaphragm (7) following a change in the liquid pressure in the liquid path (2) can be detected without contact, for recognizing an occlusion in the liquid path (2). This yields the advantage that an accurate and delay-free occlusion recognition with low system cost becomes possible.

The present invention provides accelerated detoxification methods for the treatment of a substance abuse-related condition in a subject. A method of the present invention may comprise administering to the subject an effective amount of at least one sedative (e.g, clonidine, diazepam, or olanzapine) and a micro-dose of an opioid antagonist (e.g., naltrexone or naloxone) for at least one day; optionally administering a small dose of an opiate, and administering to the subject a detoxifying amount of a second opioid antagonist (e.g., naloxone); and may further comprise administering to the subject a third opioid antagonist (such as, naltrexone) for an extended period of time (e.g., 12 months).

A microdosing device includes a dosing chamber which at least temporarily receives a quantity of liquid, and to which at least one dispensing opening is assigned. A vibration unit is operatively connected to at least one boundary surface of the dosing chamber in order to cause this boundary surface to oscillate for the purpose of a dispensing operation.At least two admission channels spaced apart from one another are provided on the dosing chamber.

Devices for the local delivery of microdose amounts of one or more active agents, alone or in combination, in one or more dosages, to selected tissue of a patient are described. The devices generally include multiple microwells arranged on or within a support structure and contain one or more active agents, alone or in combination, in one or more dosages and / or release pharmacokinetics. In an exemplary embodiment, the device has a cylindrical shape, having symmetrical wells on the outside of the device, each well containing one or more drugs, at one or more concentrations, sized to permit placement using a catheter, cannula, or stylet. Optionally, the device has a guidewire, and fiber optics, sensors and / or interactive features such as remote accessibility to provide for in situ retrieval of information and modification of device release properties. In a preferred embodiment, the fiber optics and / or sensors are individually accessible to discrete wells.

A fluid sample dispenser includes a microdosing device for outputting, during an activation state, a fluid sample at a fluid sample outlet to the environment, wherein the microdosing device is placeable adjacent to a person's nose so that a distance between the outlet of the microdosing device and a nostril of the person's nose is within a predefined range, and a microdosing driver unit for adjusting a dosing rate of the scent sample output at the scent sample outlet by selectively activating the microdosing device.

Devices for the local delivery of microdose amounts of one or more active agents, alone or in combination, in one or more dosages, to selected tissue of a patient are described. The devices generally include multiple microwells arranged on or within a support structure. The microwells contain one or more active agents, alone or in combination, in one or more dosages and / or release pharmacokinetics. In an exemplary embodiment, the device has a cylindrical shape, having symmetrical wells on the outside of the device, each well containing one or more drugs, at one or more concentrations, sized to permit placement using a catheter, cannula, or stylet. Optionally, the device has a guidewire, and fiber optics, sensors and / or interactive features such as remote accessibility (such as WiFi) to provide for in situ retrieval of information and modification of device release properties. In the most preferred embodiment, the fiber optics and / or sensors are individually accessible to discrete wells.

A microdosing device for dosing smallest quantities of a medium, having an inlet device, an outlet device, a pump device and a media duct that leads from the inlet device to the outlet device, the inlet device having an inlet opening and an inlet valve having an inlet valve piston, and the outlet device having an outlet opening and an outlet valve having an outlet valve piston, and the pump device having a pump piston. The inlet valve piston, the outlet valve piston and the pump piston are situated on a common diaphragm layer. The microdosing device has the advantage that it is able to be produced in a simple and cost-effective manner.

The present invention discloses a method to recover and restore dendritic and synaptic neuron connections that have been degraded or destroyed by neurodegenerative diseases. In the present invention tryptamines are used to induce neuro plasticity and restore both dendritic density and synaptic connections of neurons in the brain. In the preferred embodiment LSD given in micro doses can induce dendritic and synaptic genesis in neuronal networks and improve the quality of life of people with neurodegenerative diseases such as Alzheimer's, Huntington's, Multiple Sclerosis, Parkinson's and Frontotemporal dementia.

The present disclosure relates to the transdermal administration of psychedelics, such as psilocybin, psilocin, lysergic acid diethylamine (LSD), and / or ibogaine, and derivatives of these compounds, for the treatment and / or prevention and / or control of severe depression (treatment resistant), major depressive disorder, obsessive-compulsive disorder, quitting smoking, alcohol addiction, cocaine addiction, opioid addiction, anxiety (stress), adult ADHD, cluster headaches, and cancer related or other end-of-life psychological distress.

A microdosing device with a dosing chamber for the at least temporary reception of a liquid quantity, and with which is associated at least one discharge opening is provided. A vibrating unit in operative connection with at least one boundary surface of the dosing chamber is provided in order to vibrate the same for a discharge process, and with a delivery function unit connected to the vibrating unit for activating the latter during a delivery time period. A drying function unit is additionally provided and can be activated in time-separated manner with respect to the delivery function unit in order to free the dosing chamber from liquid residues.

Techniques for generating radiotherapy treatment plan parameters are provided. The technology comprises the following steps: receiving radiotherapy treatment plan information; processing the radiotherapy treatment plan information to estimate one or more radiotherapy treatment plan parameters based on processing of an output of the sub-processing dependent on the derivative of the estimated dose calculation; and generating a radiotherapy treatment plan using the estimated one or more radiotherapy treatment plan parameters.

Means and methods for dispensing small amounts of liquid from multi-channel microdispensing devices, suitable for use in automatic processing in biological assays and for the cultivation of cells andtissues, by means of optical control of the dosed liquid by specific light barrier units.

The present disclosure provides methods and devices for delivering pilocarpine to the eye. In certain aspects, the disclosure provides method for delivering a composition comprising pilocarpine to an eye of a subject in need thereof as a micro-dose stream of droplets. In certain embodiments, the method treats or alleviates one or more symptoms of presbyopia, in particular presbyopia in adults 40 years of age or older, in the subject in need thereof. In certain embodiments, the present disclosure utilizes relatively high concentrations of pilocarpine in the solution to be administered and as a single active agent.

The invention relates to a biological dose calculation method for boron neutron capture therapy (BNCT). According to the method disclosed by the invention, accurate measurement of the tumor cell scale and tumor / normal tissue vessel boron concentration distribution is realized based on a neutron autography technology; according to different boron drug distribution characteristics, neutron energy spectra and tissue material characteristics, the corresponding relationship between boron distribution and neutron energy and the relative biological effect (RBE) or the complex biological effect (CBE) of all ray components of the BNCT is constructed through Monte Carlo simulation and a microdosimetry physical model; a radiation simulation human body model of patient individualization is constructed based on the medical image data, and then, three-dimensional dose distribution is obtained; and according to contouring of a gross tumor volume and normal structures, the equivalent biological dose is acquired by combining three-dimensional physical dose distribution and biological effect factors, and the dose volume histogram (DVH) of tumors and normal structures are obtained by calculation, so that a theoretical basis is provided for the design of novel targeted drugs and biological conversion of the accurate BNCT clinical treatment plan.

The invention provides a safety valve assembly suitable for micro-dose infusion, a micro-dose secretion pump and an insulin pump. The safety valve assembly comprises a valve body, a flexible body and a needle withdrawing unit. The valve body is connected with a medium output device, the flexible body is connected between the valve body and the medium output device, and the needle withdrawing unit is connected with the valve body; the medium output device is provided with a medium inlet and outlet and a flexible body driving port, a first pipeline is arranged in the valve body, the input end of the first pipeline is connected with the medium inlet and outlet, the output end of the first pipeline is located on one side of the flexible body, and the flexible body driving port is located on the other side of the flexible body; and the sectional area of the medium inlet and outlet is smaller than that of the flexible body driving port. The problem that the medium injection speed is too high in the output failure process of medium output device can be solved, and under certain application conditions such as insulin or medicament injection, excessive injection can cause life danger.

A fluid sample dispenser includes a microdosing device for outputting, during an activation state, a fluid sample at a fluid sample outlet to the environment, wherein the microdosing device is placeable adjacent to a person's nose so that a distance between the outlet of the microdosing device and a nostril of the person's nose is within a predefined range, and a microdosing driver unit for adjusting a dosing rate of the scent sample output at the scent sample outlet by selectively activating the microdosing device.

This application is directed to a method of microdosing by dissolving drug in water and permitting a human or animal to consume the drug during waking hours. Metering for an animal is the amount of water they drink, in the pattern as consumed. By setting drug concentration so that a target dose will be consumed in a typical amount of daily drinking water, the dose is spread out into a series of smaller doses over time. For a human, this can be metered more specifically and thoughtfully. A mechanism to make this convenient for humans is provided. A model of blood levels is described. The clinical benefits are greater than predicted from extrapolating from a daily dose to dosing twice a day to a projected 6-12 times a day with the microdosing method.

The invention provides a dose-controllable medium conveying structure, a medium conveying method and a micro-dose secretion pump. The dose-controllable medium conveying structure comprises a dose output assembly, the dose output assembly comprises a first multi-way valve, a second multi-way valve and a cavity, a sealing piece is connected in the cavity, a first cavity space on one side of the sealing piece and a second cavity space on the other side of the sealing piece are independent of each other through the sealing piece, and the size of the first cavity space and the size of the second cavity change along with movement or deformation of the sealing piece. The direction of an external medium entering the dose output assembly is controlled by controlling the conduction directions of thefirst multi-way valve and the second multi-way valve; and through the pressure of the medium entering the first cavity space / the second cavity space, the sealing piece moves or deforms, the second cavity space / the first cavity space is extruded, and the medium in the second cavity space / the first cavity space is discharged. According to the invention, the effect of one-time dose delivery can be accurate, and the dose delivered for one time cannot be changed due to the influence of external factors.

The invention discloses a high-flux medicine decoction and collection device and method. The device comprises a plurality of decoction units, wherein the decoction units are arranged in an array mode;each decoction unit comprises a pressurizing chamber, a decoction, a heater and a collection capillary pipeline; air resistors are arranged on the walls of the pressurizing chambers; the air resistors are connected with the walls of the pressurizing chambers through return springs; the decoction chambers are connected with the pressurizing chambers through the air resistors; filtering membranes are arranged on the walls of the decoction chambers; the heaters are used for heating the decoction chambers; one end of each collection capillary pipeline is connected with the filtering membrane of each decoction chamber through a switch part. As multiple decoction units of an identical structure are arranged in the array mode, traditional Chinese medicines of micro dosages can be simultaneouslydecocted in a large-scale mode, and a decoction function of high fluxes and micro reactions can be achieved; and in addition, a decoction collection mode of pressurization and filtering membranes ensures that a decoction can be sufficiently collected even in case of a micro dosage, and the problem that the decoction cannot be sufficiently separated from medicine residues can be solved.

A nozzle is provided herein for ophthalmic dispensers which is configured to accommodate microdosing. The nozzle includes a converging pathway. Preferably, the pathway converges so as to impart momentum to liquid passing therethrough through an increase of velocity. A tapered portion may be provided flared openly from the inlet to best accept liquid flow thereinto and provide a funneling effect into the flowpath. Preferably, the flowpath terminates at an outlet which is internally un-radiused and circumscribed by a chamfered surface.

A dosing system for transferring an aseptic fluid in dosages into a container, comprising a peristaltic pump configured such that the filling accuracy for fill volumes of the aseptic fluid <100 μL is ±3 μL.

The invention relates to methods, systems and kits for determining therapeutic effectiveness or toxicity of cancer-treating compounds that incorporate into or bind to DNA. In particular, the invention is directed to methods, systems and kits for predicting a patient's treatment outcome after administration of a microdose of therapeutic composition to the patient or a sample from the patient. The methods provides physicians with a diagnostic tool to segregate cancer patients into differential populations that have a higher or lower chance of responding to a particular therapeutic treatment.

The invention relates to a biological dose calculation method for boron neutron capture therapy (BNCT). The method of the present invention is based on neutron autoradiography technology to realize accurate measurement of tumor cell scale and tumor / normal tissue vascular boron concentration distribution; according to the distribution characteristics of different boron drugs, neutron energy spectrum and tissue material characteristics, through Monte Carlo simulation and The microdosimetry biological model constructs the corresponding relationship between boron distribution and neutron energy and the relative biological effect (RBE) or composite biological effect (CBE) of each BNCT ray component; constructs a patient's individualized radiation simulation human body model based on medical image data, and then The three-dimensional dose distribution is obtained; according to the contours of the tumor target area and normal organs, and combined with the three-dimensional physical dose distribution and biological effect factors to obtain the equivalent biological dose, the dose-volume histogram (DVH map) of the tumor and normal tissues and organs is calculated, which is The theoretical basis is provided for the design of new targeted drugs and the biological transformation of precise BNCT clinical treatment plans.